Cell signaling

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Biology, Cell biology, Biomarkers, Biotechnology, Chemical pathology, Cell signaling, Stimulator, SGC, Branches of biology, Biology, Cell biology, Biomarkers, Biotechnology, Chemical pathology, Cell signaling, Stimulator, SGC

Preclinical data from CY6463 and extensive academic work validate the crucial role of the sGC pathway in brain physiology.

Key Points: 
  • Preclinical data from CY6463 and extensive academic work validate the crucial role of the sGC pathway in brain physiology.
  • Stimulation of sGC by CY6463 to amplify NO-sGC-cGMP signaling is a potential first-in-class approach for the treatment of CIAS.
  • Cyclerion is planning to initiate a Phase 1b signal-seeking study in CIAS to evaluate safety and near-term impact on disease-relevant biomarkers.\nCY3018, a differentiated, next-generation CNS-penetrant sGC stimulator: Cyclerion shared information on the latest development candidate, CY3018.
  • The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases.

Synthekine Licenses Additional Cytokine Programs

Retrieved on: 
Thursday, April 22, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Other Health, Branches of biology, Medical specialties, Biology, Immunology, Cell biology, Cytokine, Cell signaling

b'Synthekine Inc., an engineered cytokine therapeutics company, today announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22.

Key Points: 
  • b'Synthekine Inc., an engineered cytokine therapeutics company, today announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22.
  • These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development.\nMost cytokines are pleiotropic and drive a range of signaling responses across multiple cell types, which limits their potential as therapeutics.
  • Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious.
  • Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells

Retrieved on: 
Wednesday, April 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Biology, Signal transduction, Stem cells, Cell signaling, Evolutionary developmental biology, Cancer stem cell, Carcinogenesis, Notch signaling pathway, Hedgehog signaling pathway, Sonic hedgehog, Epithelial–mesenchymal transition

StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.

Key Points: 
  • StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.
  • "Specifically, NADI-351 clears cancer stem cells by starving them of Notch signaling and causes cell death in tumors, including esophageal and triple-negative breast cancer.
  • At the same time this breakthrough science is being published, StemSynergy Therapeutics is developing this class of compound for clinical evaluation.
  • Our mission is to optimize efficacy against the pathways required to drive cancer stem cells, such as the Wnt, Sonic Hedgehog and Notch signaling pathways.

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Retrieved on: 
Sunday, April 11, 2021
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Tyrosine kinase receptors, Cell signaling, AXL receptor tyrosine kinase, MERTK, Bruton's tyrosine kinase, Tumor microenvironment, Zanubrutinib, Vascular endothelial growth factor, TME, TYRO3, Programmed cell death protein 1, Sitravatinib, Tislelizumab, the Tislelizumab Clinical Program, BeiGene

At the time of data cutoff, 16 patients (64%) remained on study treatment.

Key Points: 
  • At the time of data cutoff, 16 patients (64%) remained on study treatment.
  • The combination of sitravatinib and tislelizumab was generally well tolerated and showed promising antitumor activity among patients with advanced PROC, including those who were heavily pretreated.
  • Sitravatinib targets the VEGFR and TAM (TYRO3, AXL, MERTK) receptor families, which are implicated in orchestrating an immunosuppressive tumor microenvironment (TME).
  • We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA\xc2\xae (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Retrieved on: 
Thursday, April 8, 2021
Research, Infectious diseases, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Branches of biology, Medical specialties, Biology, Immunology, Biotechnology, Antibody-drug conjugate, Cell signaling, Chemical specificity, Antibody, Monoclonal antibody, Cancer immunotherapy, B cell Select™, DeepDisplay™, ImmunoPrecise Antibodies Ltd.

In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.

Key Points: 
  • In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.
  • That higher specificity is expected to increase the therapeutic window by lowering the potential risk of side effects and positively impacting treatment efficacy.
  • Additionally, the targets expression profile makes this membrane protein a promising candidate for antibody-drug conjugate-based therapies.
  • Alzheimers and other neurodegenerative diseases are associated with reduced expression levels of the target and impaired receptor signaling.

BioTheryX Announces Expansion of Scientific Advisory Board

Retrieved on: 
Wednesday, April 7, 2021
Branches of biology, Biology, Signal transduction, Cell biology, Evolutionary developmental biology, Genes, Wnt signaling pathway, NF-κB, Cell signaling, Kevan Shokat

SAN DIEGO, April 7, 2021 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.

Key Points: 
  • SAN DIEGO, April 7, 2021 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.
  • His research work focuses on signaling pathways regulating innate immunity and inflammation, particularly in the context of cancer.
  • His lab deciphered key steps in the activation of the NFkB and Wnt signaling pathways and studied them in animal models of cancer.
  • This technology is designed to utilize the body's own protein disposal system to selectively degrade and remove disease-causing proteins.

VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Cell signaling, GABAA receptor positive allosteric modulators, Pherine, Steroids, PH10, Hypnotics, Psychoactive drugs, Benzodiazepine, Antidepressant, GABA receptor

Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.

Key Points: 
  • Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.
  • In September 2020, the U.S. Food and Drug Administration (FDA) released a Drug Safety Communication (DSC) detailing the risks associated with use of benzodiazepines.
  • PH10 is a new generation antidepressant with a mechanism of action that is designed to be fundamentally different from all current FDA-approved antidepressants.
  • PH10 is a Phase 2 investigational pherine nasal spray designed to have rapid-onset effects and therapeutic potential in several neuropsychiatric indications involving depression.

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Biology, Cell biology, Neuropilin 2, Single-pass transmembrane proteins, aTyr Pharma, Neuropilin, Aminoacyl tRNA synthetase, Signal transduction, Cell signaling

Details of the poster presentations are as follows:

Key Points: 
  • Details of the poster presentations are as follows:
    Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses.
  • In many forms of cancer, high NRP2 expression is associated with worse outcomes.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference

Retrieved on: 
Tuesday, February 23, 2021
Branches of biology, Glutamate, Biology, NMDA receptor antagonists, Ionotropic glutamate receptors, Cell signaling, Molecular neuroscience, NMDA receptor, SVB Leerink, N-Methyl-D-aspartic acid, Choline acetyltransferase

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- RelmadaTherapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:40 p.m. Eastern Time.

Key Points: 
  • NEW YORK, Feb. 23, 2021 /PRNewswire/ -- RelmadaTherapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:40 p.m. Eastern Time.
  • A live webcast of the fireside chat will be available by visiting the investors section of the Company's website at www.relmada.com .
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Outlook on the Apoptosis Assay Global Market to 2028 - by Product, Technique, Assay Type, End-use and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, February 22, 2021
Pharmaceutical, Health, Oncology, Other Health, Branches of biology, Biology, Programmed cell death, Cell biology, Cell signaling, Laboratory techniques, Apoptosis, Assay, DNA fragmentation, Fragmentation, Caspase, Mitochondrion

The global apoptosis assay market size is expected to reach USD 8.20 billion by 2028, according to the study.

Key Points: 
  • The global apoptosis assay market size is expected to reach USD 8.20 billion by 2028, according to the study.
  • This report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The global apoptosis assay industry is fragmented based on product, technique, assay type, end-use, and region.
  • Based on the assay type, the apoptosis test market is classified as Caspase, DNA Fragmentation, Cell Permeability, and Mitochondrial.